Payment overview · 2025
General Payments
$1,028.27
21 reported records · 12 companies
Healthcare provider profile · identity verified
Sami A Nafoosi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LANCASTER, CA · NPI 1164713244
Verified facts
What the public records show
CMS Open Payments records show Sami A Nafoosi, MD received $1,028.27 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $174.66 | 17.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $168.65 | 16.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $150.70 | 14.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.88 | 13.8% | 3 | 2025 |
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $129.94 | 12.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $116.23 | 11.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.89 | 3.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.99 | 2.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.60 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.77 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.87 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.09 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,028.27 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $168.65 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $162.20 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $150.70 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $141.88 | 3 | 2025 |
Source payment records
|
|||||
| EYLEA Normalized: eylea |
Biological | Regeneron Pharmaceuticals, Inc. | $129.94 | 1 | 2025 |
Source payment records
|
|||||
| EYLEA HD Normalized: eylea hd |
Biological | Regeneron Pharmaceuticals, Inc. | $129.94 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $116.23 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.89 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $12.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 181 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 196 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 168 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 59 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
196 | 55 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
168 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
169 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
181 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 894 | 277 |
| Amlodipine Besylate | Amlodipine Besylate | 538 | 170 |
| Levothyroxine Sodium | Levothyroxine Sodium | 493 | 124 |
| Lisinopril | Lisinopril | 478 | 142 |
| Omeprazole | Omeprazole | 383 | 98 |
| Losartan Potassium | Losartan Potassium | 316 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 301 | 92 |
| Metformin Hcl | Metformin Hcl | 269 | 90 |
| Gabapentin | Gabapentin | 238 | 77 |
| Alendronate Sodium | Alendronate Sodium | 235 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 204 | 67 |
| Farxiga | Dapagliflozin Propanediol | 196 | 55 |
| Lovastatin | Lovastatin | 187 | 65 |
| Pioglitazone Hcl | Pioglitazone Hcl | 187 | 64 |
| Simvastatin | Simvastatin | 184 | 59 |
| Furosemide | Furosemide | 182 | 61 |
| Eliquis | Apixaban | 181 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 60 |
| Ozempic | Semaglutide | 169 | 38 |
| Jardiance | Empagliflozin | 168 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 52 |
| Tramadol Hcl | Tramadol Hcl | 153 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 40 |
| Baclofen | Baclofen | 138 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 131 | 49 |
| Lorazepam | Lorazepam | 111 | 38 |
| Metformin Hcl Er | Metformin Hcl | 109 | 34 |
| Carvedilol | Carvedilol | 108 | 34 |
| Ibuprofen | Ibuprofen | 107 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 104 | 27 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 103 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 30 |
| Montelukast Sodium | Montelukast Sodium | 94 | 20 |
| Benazepril Hcl | Benazepril Hcl | 92 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 33 |
| Glimepiride | Glimepiride | 91 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 27 |
| Sertraline Hcl | Sertraline Hcl | 86 | 28 |
| Atenolol | Atenolol | 85 | 25 |
| Finasteride | Finasteride | 79 | 29 |
| Clonidine Hcl | Clonidine Hcl | 76 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 23 |
| Trazodone Hcl | Trazodone Hcl | 76 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 26 |
| Azithromycin | Azithromycin | 66 | 53 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 25 |
| Alprazolam | Alprazolam | 65 | 19 |
| Kerendia | Finerenone | 59 | 15 |
| Potassium Chloride | Potassium Chloride | 59 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 14 |
| Xarelto | Rivaroxaban | 58 | 18 |
| Hydrocortisone | Hydrocortisone | 57 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 21 |
| Allopurinol | Allopurinol | 55 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 52 | 18 |
| Sildenafil Citrate | Sildenafil Citrate | 50 | 13 |
| Valsartan | Valsartan | 50 | 15 |
| Chlorthalidone | Chlorthalidone | 49 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 20 |
| Entresto | Sacubitril/Valsartan | 49 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 19 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 47 | suppressed |
| Spironolactone | Spironolactone | 45 | 17 |
| Donepezil Hcl | Donepezil Hcl | 44 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 11 |
| Famotidine | Famotidine | 40 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | 15 |
| Ketoconazole | Ketoconazole | 39 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 15 |
| Warfarin Sodium | Warfarin Sodium | 39 | 11 |
| Glipizide | Glipizide | 38 | 13 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 16 |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Rybelsus | Semaglutide | 37 | suppressed |
| Estradiol | Estradiol | 36 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 11 |
| Ezetimibe | Ezetimibe | 32 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 30 | 17 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 30 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | 14 |
| Naproxen | Naproxen | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Prednisone | Prednisone | 18 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,028.27 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EYLEA, EYLEA HD, FARXIGA, JARDIANCE, JOURNAVX, Kerendia, REXULTI, TRELEGY ELLIPTA, VRAYLAR, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error